(c) 2024 PillSync.com

carisoprodol tablet

1 INDICATIONS AND USAGE Carisoprodol Tablets USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Carisoprodol Tablets USP should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see Dosage and Administration (2) ]. Carisoprodol Tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. (1) Limitations of Use: Should only be used for acute treatment periods up to two or three weeks (1)

aphena pharma solutions - tennessee, llc


6 years ago ROUND WHITE 2410 V carisoprodol tablet

ROUND WHITE 2410 V

16 HOW SUPPLIED/STORAGE AND HANDLING Repackaged by Aphena Pharma Solutions - TN. See Repackaging Information for available configurations. Carisoprodol Tablets USP, 350 mg: white, round, unscored tablets debossed "2410 V" on one side and plain on the reverse side; available as follows: Bottles of 100: NDC 0603-2582-21 Bottles of 500: NDC 0603-2582-28 Bottles of 1000: NDC 0603-2582-32 Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].


More pills like ROUND 2410 V

Related Pills

carisoprodol tablet

Par Pharmaceutical

Carisoprodol 350 MG Oral Tablet

Par Pharmaceutical

carisoprodol tablet

par pharmaceutical

carisoprodol tablet

par pharmaceutical

carisoprodol tablet

par pharmaceutical

carisoprodol tablet

par pharmaceutical

carisoprodol tablet

par pharmaceutical

carisoprodol tablet

par pharmaceutical












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site